The insider transactions over the last year suggest optimism about the company's future. The level of insider ownership indicates a reasonable degree of alignment with common shareholders.
Christine Kho楼主TinkerB3ll:
assay quality issue and drop in Asia Pacific market share...technically bottom volumn > peak volumn is good entry price...purposely oversold...soon will see back to 8-9
Gainers •$MillerKnoll(MLKN.US)$+12.4%,$BioNTech(BNTX.US)$+7.4%,$Lululemon Athletica(LULU.US)$+6.5% (also authorizes $1 bln stock repurchase program) •$Adagio Therapeutics(ADGI.US)$+52.47% (announces ADG20 (adintrevimab) is the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19 and plans to seek US emergency use authorization) ...
18
8
2
举报
CraCra665 :
I'd personally go for the ones w the losses. because that when I gst in. on the dips. I'm not jumping into anything up like that. I maybe wrong. but that's how I feel. get in high when drop comes. ur in the negative. not a smart move in my mind.
RDK79 :
Very glad moomoo provides excellent business news, especially as CNBC transitions all of its business news to a WAY OVERPRICED ‘CNBC Pro’ service. Very little regular relevant business news via CNBC these days.
Quanterix股票讨论区
ABOS PEPG TOPS AAPL DIS XPEV MNMD TSM QTRX
$Acumen Pharmaceuticals(ABOS.US)$ $PepGen(PEPG.US)$ $Top Ships(TOPS.US)$ $苹果(AAPL.US)$ $迪士尼(DIS.US)$ $小鹏汽车(XPEV.US)$ $Mind Medicine(MNMD.US)$ $台积电(TSM.US)$ $Quanterix(QTRX.US)$
In reaction to earnings/guidance:
• $GoodRx(GDRX.US)$ +38.5%, $EDGIO(EGIO.US)$ +13.5%, $Lemonade(LMND.US)$ +10.7%, $Desktop Metal(DM.US)$ +8.5%, $ShockWave Medical(SWAV.US)$ +8.2%, $Pubmatic(PUBM.US)$ +8.1%, $Olaplex(OLPX.US)$ +7%, $Vivid Seats(SEAT.US)$ +6.4%, $Noble(NE.US)$ +6.3%, $艾斯本科技(AZPN.US)$ +5.4%, $艾伦建材(AAON.US)$ +5%, $Hudbay Minerals(HBM.US)$ +5%, $Vivint Smart Home(VVNT.US)$ +4.9%, $Vivint Smart Home(VVNT.US)$ +4...
• $MillerKnoll(MLKN.US)$ +12.4%, $BioNTech(BNTX.US)$ +7.4%, $Lululemon Athletica(LULU.US)$ +6.5% (also authorizes $1 bln stock repurchase program)
• $Adagio Therapeutics(ADGI.US)$ +52.47% (announces ADG20 (adintrevimab) is the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19 and plans to seek US emergency use authorization)
...
暂无评论